Syntheses and anti-cancer activities of 2-[1-(indol-3-yl-/pyrimidin-5-yl-/pyridine-2-yl-/quinolin-2-yl)-but-3-enylamino]-2-phenyl-ethanols

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 6, 2007, Pages 2386-2395

  Singh, Palwinder ^a   Kaur, Pervinder ^a   Luxami, Vijay ^a   Kaur, Satwinderjit ^a   Kumar, Subodh ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Allylation; Anti cancer activities; Heterocycles; In vitro; Indium; Schiff bases

Indexed keywords

1,3 BIS(2 CHLOROBENZYL) 5 [1 (2 HYDROXY 1 PHENYLAMINO)BUT 3 ENYL] 1H PYRIMIDIN 2,4 DIONE; 1,3 BIS(2 CHLOROBENZYL) 5 [1 (2 HYDROXY 1 PHENYLETHYLAMINO)BUT 3 ENYL] 1H PYRIMIDIN 2,4 DIONE; 2 PHENYL 2 (1' PYRIDIN 2 YLBUT 3' ENYLAMINO)ETHANOL; 2 PHENYL 2 (1' QUINOLIN 2 YLBUT 3' ENYLAMINO)ETHANOL; 3 (1 BENZYLAMINOBUT 3 ENYL)INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 (1 DIBENZYLAMINOBUT 3 ENYL)INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (1 HYDROXYMETHYL 2 METHYLPROPYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (2 HYDROXY 1 PHENYLETHYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (2 HYDROXYETHYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (2 METHOXYPHENYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (4 CHLOROBENZYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; 3 [1 (4 METHOXYPHENYLAMINO)BUT 3 ENYL]INDOLE 1 CARBOXYLIC ACID ETHYL ESTER; ALDEHYDE; AMINE; ANTINEOPLASTIC AGENT; INDIUM; INDOLE; METHYL GROUP; PYRIDINE; PYRIMIDINE; QUINOLINE; SCHIFF BASE; UNCLASSIFIED DRUG;

ALLYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMICAL REACTION KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MOLECULAR STRUCTURE; NEOPLASMS; PYRIDINES; PYRIMIDINES; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33846917985     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.01.018     Document Type: Article

References (49)

1. Nitiss J.L. Biochem. Biophys. Acta 1400 (1998) 63
2. Wang J.C. Nat. Rev. Mol. Cell Biol. 3 (2002) 430
3. Fantin V.R., St-Pierre J., and Leder P. Cancer Cell 9 (2006) 425
4. Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., Ishikawa M., and Yamada Y. Nature 356 (1992) 668
5. Haraguchi M., Miyadera K., Uemura K., Sumizawa T., Furukawa T., Yamada Y., and Akiyama S. Nature 368 (1994) 198
6. Matsushita S., Nitanda T., Furukawa T., Sumizawa T., Tani A., Nishimota K., Akiba S., Miyadera K., Fukushima M., Vamada Y., Yoshida H., Kanzaki T., and Akiyama S. Cancer Res. 59 (1999) 1911
7. Sakamoto S., Kuwa K., Tsukada K., Sagara T., Noriyuki K., and Okamoto R. Carcinogenesis 8 (1987) 405
8. Carreras C.W., and Santi D.V. Annu. Rev. Biochem. 64 (1995) 721
9. Rode W., and Les A. Acta Biochim. Pol. 43 (1996) 133
10. NIH, USA, has classified the anticancer drugs according to their mechanism of action. See NIH website: www.dtp.nci.nih.gov/.
11. Teodori E., Dei S., Scapecchi S., and Gualtieri F. IL Farmaco 57 (2002) 385
12. Krishna R., and Mayer L.D. Eur. J. Pharm. Sci. 11 (2000) 265
13. Sundberg R.J. In: Katritzky A.R., and Rees C.W. (Eds). Comprehensive Heterocyclic Chemistry II Vol. 4 (1996), Oxford, Pergamon 370-376
14. Fritz J.E., Hipskind P.A., Lobb K.L., Nixon J.A., Threlkeld P.G., Gitter B.D., McMillian C.L., and Kaldor S.W. Bioorg. Med. Chem. Lett. 11 (2001) 1643
15. Meagher K.L., Mewshaw R.E., Evrard D.A., Zhou P., Smith D.L., Scerni R., Spangler T., Abulhawa S., Shi X., Schechter L.E., and Andree T.H. Bioorg. Med. Chem. Lett. 11 (2001) 1885
16. Andreani A., Granaiola M., Leoni A., Locatelli A., Morigi R., Rambaldi M., Garaliene V., Farruggia G., and Masotti L. Bioorg. Med. Chem. 12 (2004) 1121
17. Lehr M. J. Med. Chem. 40 (1997) 2694
18. Stolc S. Life Sci. 65 (1999) 1943
19. Tfelt-Hansen O., De Vries P., and Saxena P.R. Drugs 60 (2000) 1259
20. Baraldi P.G., Tabrizi M.A., Preti D., Bovers A., Fruttarolo F., Romagnoli B., Zaid N.A., Moorman A.R., Varani K., and Borea P.A. J. Med. Chem. 48 (2005) 5001
21. Davioud-Charvet E., Delarue S., Biot C., Schwobel B., Boehme C.C., Mussigbrodt A., Maes L., Sergheaert C., Grellier P., Schirmer R.H., and Becker K. J. Med. Chem. 44 (2001) 4268 and references therein
22. Mekouar K., Mouscadet J.-F., Desmaele D., Subra F., Leh H., Savoure D., Auclair C., and d'Angelo J. J. Med. Chem. 41 (1998) 2846
23. Ma Z., Hano Y., Nomura T., and Chen Y. Heterocycles 46 (1997) 541
24. Sun F., and Xing Q.Y. J. Nat. Prod. 52 (1989) 1180
25. Wild D., Toth G., and Humpf H.-U. J. Agric. Food Chem. 51 (2003) 5493
26. Hockova D., Holy A., Masojidkova M., Andrei G., Snoeck R., De Clerq E., and Balzarini J. Bioorg. Med. Chem. 12 (2004) 3197 and references therein
27. Breyholz H.-J., Schafers M., Wagner S., Holtke C., Faust A., Rabeneck H., Levkau B., Schober O., and Kopka K. J. Med. Chem. 48 (2005) 3400
28. Morphy R., and Rankovic Z. J. Med. Chem. 48 (2005) 6523
29. Charlier C., and Michaux C. Eur. J. Org. Chem. 38 (2003) 645
30. de Leval X., Julemont F., Delarge J., Pirotte B., and Dogne J.-M. Curr. Med. Chem. 9 (2002) 941
31. Pommery N., Taverne T., Telliez A., Goossens L., Charlier C., Pommery J., Goossens J.-F., Houssin R., Durant F., and Henichart J.P. J. Med. Chem. 47 (2004) 6195
32. Singh P., and Paul K. Bioorg. Med. Chem. 14 (2006) 8622
33. Lu W., and Chan T.H. J. Org. Chem. 65 (2000) 8589
34. Lu W., and Chan T.H. J. Org. Chem. 66 (2001) 3467
35. Vilaivan T., Winotapan C., Shinada T., and Ohfune Y. Tetrahedron Lett. 42 (2001) 9073
36. Bernardi L., Cere V., Femoni C., Pollicino S., and Ricci A. J. Org. Chem. 68 (2003) 3348
37. Loh T.P., Ho D.S.C., Xu K.C., and Sim K.Y. Tetrahedron Lett. 38 (1997) 865
38. Kumar S., Kumar V., and Chimni S.S. Tetrahedron Lett. 41 (2000) 5073
39. Berger R., Rabbat P.M.A., and Leighton J.L. J. Am. Chem. Soc. 125 (2003) 9596
40. 3CN.
41. Kumar S., Kaur P., Mittal A., and Singh P. Tetrahedron 62 (2006) 4018
42. Singh P., Mittal A., Kaur P., and Kumar S. Tetrahedron 62 (2006) 1063
43. Kaur P., Singh P., and Kumar S. Tetrahedron 61 (2005) 8231
44. Malik V., Singh P., and Kumar S. Tetrahedron 61 (2005) 4009
45. Malik V., Singh P., and Kumar S. Tetrahedron 62 (2006) 5944
46. 3-DMF mediated formylation of 1,3-bis-(2-chlorobenzyl)-pyrimidin-2,4-dione.
47. Ally M.C., Scudiero D.A., Monks P.A., Hursy M.L., Czerwinski M.J., Fine D.A., Abbott B.J., Mayo J.G., Showmaker R.H., and Boyd M.R. Cancer Res. 48 (1988) 589
48. Grever M.R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622
49. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91